KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Enterprise Value (2016 - 2026)

Pacific Biosciences Of California has reported Enterprise Value over the past 16 years, most recently at -$279.5 million for Q4 2025.

  • For Q4 2025, Enterprise Value rose 28.32% year-over-year to -$279.5 million; the TTM value through Dec 2025 reached -$279.5 million, up 28.32%, while the annual FY2025 figure was -$279.5 million, 28.32% up from the prior year.
  • Enterprise Value for Q4 2025 was -$279.5 million at Pacific Biosciences Of California, up from -$298.7 million in the prior quarter.
  • Over five years, Enterprise Value peaked at -$76.9 million in Q1 2024 and troughed at -$1.1 billion in Q2 2021.
  • A 5-year average of -$609.8 million and a median of -$631.4 million in 2023 define the central range for Enterprise Value.
  • Biggest five-year swings in Enterprise Value: tumbled 1166.75% in 2021 and later soared 91.21% in 2024.
  • Year by year, Enterprise Value stood at -$1.0 billion in 2021, then rose by 26.05% to -$772.3 million in 2022, then grew by 18.24% to -$631.4 million in 2023, then soared by 38.24% to -$389.9 million in 2024, then rose by 28.32% to -$279.5 million in 2025.
  • Business Quant data shows Enterprise Value for PACB at -$279.5 million in Q4 2025, -$298.7 million in Q3 2025, and -$314.7 million in Q2 2025.